Introduction {#S1}
============

Hematopoietic cell transplantation (HCT) is effective therapy for many patients with high-risk hematologic malignancies.^[@R1]^ Unfortunately, even with enormous volunteer donor registries, a substantial number of patients remain without an available HLA-matched related or unrelated donor.^[@R2]^ These patients then must undergo HCT using an alternative HLA-mismatched source such as unrelated umbilical cord blood or related haploidentical donor.^[@R3]-[@R5]^ Haploidentical donors are viable alternatives, as family members are highly motivated and readily available for a majority of patients.^[@R6]^ Initial success with haploidentical donors was achieved using grafts that were extensively T-cell depleted ex vivo.^[@R7]-[@R12]^ However, these transplants were met with relatively high rates of graft failure, relapses, or infections due to delayed hematopoietic and immune reconstitution.^[@R13],\ [@R14]^ More recently developed haploidentical donor HCT approaches have diminished some of these early challenges. T-cell replete haploidentical donor transplant has been increasingly utilized and demonstrate outcomes comparable to those of sibling donor transplantations.^[@R15]-[@R20]^ Other recent T-cell depleted haploidentical donor transplantation regimens employ selective T-cell depletion techniques^[@R9]^ or selected T-cell add back procedures^[@R14]^ to alleviate the risks of rejection, acute GvHD, infection, and relapse.

When T cells are depleted either ex vivo or in vivo, the patient must wait for the slow process of de novo T-cell production and education.^[@R21]^ Therefore, a selective T-cell depletion method that depletes naïve T cells to prevent GvHD but preserves memory cells would provide immediate functional T cells with anti-infection, anti-leukemia^[@R22]^, and anti-rejection effects weeks to months before de novo T-cell development.^[@R23],\ [@R24]^ One such technique is selective depletion of the CD45RA+ subset.^[@R25],\ [@R26]^ CD45, also called leukocyte common antigen, is expressed on all white cell lineages. Naïve T cells express CD45RA, until exposure to its cognate antigen, when there is a switch to the CD45RO isoform.^[@R27]^

Herein, we describe the results of CD45RA+ cell depletion of haploidentical donor grafts and early immune reconstitution in patients with poor-prognosis hematologic malignancies. We found reliable engraftment with promising early memory T-cell reconstitution and a low rate of acute GvHD.

Methods {#S2}
=======

Patient Selection {#S3}
-----------------

Patients with a poor-prognosis hematologic malignancy for which HCT is indicated, or with chemotherapy-refractory leukemia, who lack an available suitable HLA-matched related or unrelated donor, and have a KIR receptor-ligand mismatched haploidentical donor, are offered enrollment on this research protocol. Additional eligibility criteria include left ventricular ejection fraction \>40%, creatinine clearance ≥50 ml/min/1.73m^2^, forced vital capacity ≥50% of predicted, performance score ≥50, total bilirubin ≤3 times the upper limit of normal (ULN), and alanine aminotransferase ≤5 ULN. The protocol was approved by the St. Jude Children's Research Hospital Institutional Review Board. The protocol is open under FDA approved IDE for the use of the CliniMACS device. Written informed consent was obtained from the patient, parent or guardian, and assent from the patient, as appropriate. This trial is registered at [ClinicalTrials.gov](http://ClinicalTrials.gov), Identifier:NCT01807611. The first 17 consecutive treated patients are presented in this study.

Treatment {#S4}
---------

Recipients received a preparative regimen that consisted of 8 Gy total lymphoid irradiation (TLI) over 4 equal fractions, 150mg/m^2^ fludarabine divided daily over 5 days, a single dose of cyclophosphamide at 60mg/kg, thiotepa 10mg/kg divided twice daily for one day, and melphalan 140mg/m^2^ divided daily over two days. On Day 0, the patients received their first hematopoietic progenitor cell graft (HPC), which was CD34+ enriched. The following day, they received a second HPC that was CD45RA-depleted. On Day +6, they received an NK cell infusion from the HPC donor. G-CSF was started Day +7. Sirolimus (n=9) or mycophenolate mofetil (MMF) (n=8) was started one week following NK cell graft infusion, with plans to stop before Day +60 if absence of circulating naïve T cells was confirmed.

Graft Preparation {#S5}
-----------------

HPCs were obtained via G-CSF mobilization of the haploidentical donor, and collection by leukapheresis on day 5 and 6 of G-CSF. The first HPC product collected on day 5 was T-cell-depleted using the CliniMACS device and CD34 Microbead (Miltenyi Biotec, Auburn, CA, USA). Minimum cell dose required for the CD34+ enriched progenitor cell graft was 2 × 10^6^ CD34+ cells/kg. Maximum CD3+ dose allowed for the CD34+ enriched HPC was 0.1 × 10^6^ CD3+ cells/kg.

The HPC product collected on day 6 was processed for CD45RA+ cell depletion using the CliniMACS device and its "Depletion 3.1" software. There was no target CD34+ dose or CD3+ dose on the CD45RA+ depleted product; however release criteria of the product includes a ≥2 log~10~ depletion of CD45RA+ cells. Two of the 17 patients did not meet the minimum CD45RA depletion after a single depletion step. Per standard operating procedure, a second run under the same conditions was performed and the requisite level of depletion was achieved in both products.

The NK cell product was collected by leukapheresis 5 days after the second HPC collection. It was a nonmobilized product, and was processed on the CliniMACS device as previously described.^[@R28],\ [@R29]^ All three cell products were infused fresh.

Post-transplant evaluations {#S6}
---------------------------

Outcomes are censored as of October 29, 2014. Complete blood counts were performed daily until neutrophil engraftment. Chimerism studies were performed weekly on peripheral blood by variable number tandem repeat analysis until Day +100 and then monthly. Patients were monitored at least weekly for the first 100 days for CMV, EBV, and adenoviral viremia by PCR. Patients who received treatment for viral infection or reactivation were captured. Flow cytometry quantification of lymphocyte subsets, and lymphocyte response to mitogens were performed at Day +30, +60, +100, and +180, and TREC and V~β~ spectratyping were performed at Day +100 in all patients who were alive without relapse.

Flow cytometry {#S7}
--------------

Flow cytometry analysis was performed to quantify lymphocyte subsets on BD LSR II flow cytometer with BD FACS DIVA software (BD Biosciences, Heidelberg, Germany). The following antibodies were used for phenotypic analysis: CD45-FITC, CD19/20-PE, CD14-Cy-7, CD25-FITC, CD127-PE, CD45RA-APC, CD3-APC Cy-7, CD8-FITC, CD4-PE, CD4-APC Cy7, CD8-APC Cy7, CD62L-FITC, CCR7-PE, CD27-FITC, CD62L-PE, (Beckton Dickinson, Franklin Lakes, NJ, USA), CD3-ECD, CD56-APC, CD45RO-ECD (Beckman Coulter, Miami, FL, USA).^[@R30]^

TCR β chain CDR3 spectratyping {#S8}
------------------------------

TCR Vβ CDR3 size spectratyping was performed by RT-PCR with 25 forward TCR Vβ subfamily--specific primers and a FAM-labeled reverse Cβ primer as described previously.^[@R31],\ [@R32]^ Denatured PCR products were electrophoresed and analyzed using 3130*xl* Genetic Analyzer (Applied Biosystems, Foster City, CA). Spectratype complexity score is calculated as the summation of number of subfamilies (i.e. 25) per score with a maximum possible score of 200 (8 peaks for each family and 25 families; 8 × 25 = 200).

Quantification of Single-Joint TREC {#S9}
-----------------------------------

Quantification of sj-TREC was performed by real-time PCR using 7900HT Fast Real-time PCR system. sj TREC and Cα pDNA were made as previously described.^[@R33]^ TREC copies per milliliter blood were reported.

Lymphocyte proliferation assay and alloreactivity {#S10}
-------------------------------------------------

Antigen-specific and mitogen-activated lymphocyte proliferation assay was performed using the DELFIA Cell Proliferation Kit (PerkinElmer Life Sciences, Turku, Finland). The following antigens and mitogen were used: CMV purified lysate, and HSV purified lysate 0.1 μg /ml (Advanced Biotechnologies Inc., Columbia, MD, USA); Tetanus Toxoid 1 μg/ml (Sanofi Pasteur Inc., Swiftwater, PA,USA); and PHA 1 μg/ml (Sigma, St. Louis, MO, USA). 100 μl of antigen/mitogen and 1×10^5^ cells were dispensed to each well in the 96 well plate. The antigen/mitogen stimulated cells were incubated at 37°C in 5% CO2 for 96 hours. On day 5, the stimulated cells were labeled by Brdu solution followed by developing the Eu-fluorescence as the manufacturer's instruction and measured the Eu-fluorescence counts using Victor2 1420 multilabel counter (PerkinElmer Life Sciences, Turku, Finland). Eu-Fluorescence Counts were reported.

CD45RA+ or CD45RA- fractions from healthy donors were stimulated in mixed leukocyte reaction (MLR) at 1:1 ratio with irradiated (30Gy) allogeneic PBMCs derived from other healthy donors for 96 hours. DELFIA Cell Proliferation Kit (PerkinElmer Life Sciences, Turku, Finland) was used to measure T-cell-mediated alloreactivity as the manufacture's instruction. Eu-Fluorescence Counts were reported.

Statistical analysis {#S11}
--------------------

Summary statistics including median and range for continuous variables and frequency for categorical variables were provided. The cumulative incidences of cell recovery, acute GVHD, full donor chimerism, relapse, transplant related mortality (TRM) were estimated using the Kalbfleisch and Prentice method, adjusting for competing risk factors. The cumulative incidence (CI) of an event was defined as the time from transplantation until event, censoring those without events at last follow-up. In the estimation of CI of cell recovery, acute GVHD, full donor chimerism and relapse, TRM was considered a competing event. In the estimation of CI of TRM, relapse was considered a competing event.

Results {#S12}
=======

Patients {#S13}
--------

Seventeen consecutive patients have received transplantation and are at least 100 days post-transplantation at the time (October 29, 2014) the data was frozen for analyses. Sixteen patients had acute leukemia, of which 10 had detectable disease (2 in morphologic remission with molecularly detectable disease, 8 with active disease - median 19%) at the time of HCT. One patient had therapy-related myelodysplastic syndrome with some response (blasts \<5%) to hypomethylation chemotherapy.([Table 1](#T1){ref-type="table"}) All received three parental haploidentical donor-cell products. The first product was given as a primary source of hematopoietic progenitor cells. It was CD34+ enriched, and provided a median CD34+ and CD3+ dose of 11.2 (range 2.0 to 38.4) and 0.012 (range 0.002 to 0.088) ×10^6^/kg, respectively.

CD45RA+ cell depletion {#S14}
----------------------

The second product was provided to adoptively transfer a large number of donor memory T cells and additional progenitor cells. The median pre- and post-processing values for the CD45RA-depleted progenitor cell grafts are detailed in [Table 2](#T2){ref-type="table"}. After processing, the CD34+ cell dose was a median of 6.4 (range 1.7 to 31.6) ×10^6^/kg, and the median recovery of CD34+ cells post-processing was 59.6%. Thus, the combined CD34+ cell dose of the two progenitor cell grafts was a median of 17.8 (range 3.6 to 67.5) ×10^6^/kg. After CD45RA+ cell depletion, the CD3+ cell dose was a median of 121.8 (range 23.6 to 528.4) ×10^6^/kg. The CD3+CD45RA+ cell dose was a median of \<0.001 (range \<0.001 to 0.128) ×10^6^/kg. The median log~10~ depletion of CD45RA+ cells was 3.6 (range 2.3 to 3.95), and the median log~10~ depletion of CD3+CD45RA+ cells was \>5.23 (range 2.35 to \>6.10). The CD19+ cell dose was a median of 0.15 (range 0.02 to 2.7) ×10^6^/kg. [Figure 1A](#F1){ref-type="fig"} shows representative flow cytometry from pre- and post-processing -- demonstrating profound depletion of CD45RA+ T cells and B cells. Post-processing samples from the CD45RA+ fraction and CD45RA-depleted fraction were assessed immunologically for the first two donor grafts. In comparison to CD45RA+ cells, in both cases the CD45RA-- sample demonstrated superior proliferative responses to antigens (CMV, EBV, HSV, tetanus), similar response to mitogen (PHA), and reduced proliferation in a MLR assay against third-party cells.([Supplemental Figure 2](#SD2){ref-type="supplementary-material"})

NK-cell Enrichment {#S15}
------------------

The third and final donor cell product was given to provide additional donor NK cells in the early post-transplant period. The median pre- and post-processing values for the NK-cell enriched grafts are detailed in [Table 2](#T2){ref-type="table"}. These products were highly purified for NK cells, with a median CD3-CD56+ cell purity of 96.4%. The median NK-cell dose was 13.11 (range 1.65 to 56.10) ×10^6^/kg. After processing, the CD3+CD56-- T-cell dose was a median of \<0.01 (range \<0.01 to 0.01) ×10^6^/kg. The median log~10~ depletion of CD3+CD56-- cells was \>4.16. The CD19+ cell dose was a median of 0.04 (range \<0.01 to 1.07) ×10^6^/kg.

Outcomes {#S16}
--------

All patients achieved neutrophil engraftment at a median of 10 (range 9 to 13) days post-transplant.([Figure 2](#F2){ref-type="fig"}) The median time to platelet engraftment was 17 (range 10-102) days post-transplant. The median time to 100% donor chimerism was Day +11. One patient (UPN 14) experienced a post-engraftment fall in donor chimerism in conjunction with the development of anti-D antibodies (Donor O+, Recipient O-). He was successfully returned to 100% donor with G-CSF-mobilized DLI.

To date, three patients have received anti-viral treatment for CMV reactivation. None have progressed to CMV disease, and all cleared CMV viremia without donor lymphocyte infusion (DLI). One patient received anti-viral treatment for adenoviral viremia. That patient developed hemorrhagic cystits with urine positive for adenovirus, which resolved without DLI. No patient has developed post-transplant lymphoproliferative disease nor have any received treatment for EBV reactivation. One patient experienced HSV reactivation, with oral HSV occurring prior to engraftment and resolving within two weeks. Other significant viral infections which occurred include four cases of community acquired rotavirus and one case of community acquired influenza A. No patient has died with a viral infection.

Thirteen patients (76.5%) remain alive at a median of 223 (range 174 to 469) days post-transplant. One patient died suddenly with arrhythmia on Day +13, and another of culture negative acute respiratory distress syndrome on Day +74. Two patients have relapsed, and both subsequently died with progressive disease.([Table 3](#T3){ref-type="table"})

No patient has developed acute GvHD. Six patients have presented with clinical features of chronic oral GvHD, and 3 of the 6 also had skin findings. Five patients experienced resolution with topical therapy alone. One patient had progression despite topical therapy, responded rapidly to tacrolimus and oral corticosteroid, and is now quiescent on weaning low dose prednisone. No patient has developed severe^[@R34]^ chronic GvHD.

\*A comprehensive review of enrolled subjects by internal and extramural experts concluded that three of the 17 patients had clinical findings consistent with acute GvHD⩾grade III. The authors agree with this independent consensus and thus, the incidence of grade III/IV acute GvHD should be reported as 17.6%, rather than zero.

Quantitative Lymphocyte Reconstitution {#S17}
--------------------------------------

Quantitative values for NK cells and CD8+ T cells rapidly reached normal values in the peripheral blood.([Figure 2](#F2){ref-type="fig"}) At Day +30, 11 of the 16 surviving patients had normal number of CD8+ T cells and 15 had a normal number of NK cells.([Table 3](#T3){ref-type="table"}) CD4+ T cells reconstituted to a median of 160 cells/μL at Day +30. As expected, B cells were virtually absent in the peripheral blood due to effective B cell depletion.

[Figure 3](#F3){ref-type="fig"} further details lymphocyte subset recovery. By Day +30, a majority of patients demonstrated a substantial number of both CD8+CD45RA-- and CD4+CD45RA-- memory T cells.([Figure3B](#F3){ref-type="fig"}) There was no sign of exhaustion, as the number of memory cells in both CD4+ and CD8+ subsets remained stable during the six-month observation period. The proportion of regulatory T cells (CD25^bright^CD127--) in the CD4+ T-cell fraction was high in the early post-transplant period, before returning to donor level.([Figure 3C](#F3){ref-type="fig"}) In the first 100 days after transplantation, we confirmed that there was a paucity of all naïve T-cell subsets (CD27+CD45RA+; CD62L+CD45RA+; and particularly the most naïve population CCR7+CD45RA+).([Figure 3D-F](#F3){ref-type="fig"}) Thus, the distribution of T-cell subsets recapitulated the CD45RA-depleted graft composition([Figure 1A](#F1){ref-type="fig"}). These data suggest that the T cells present in the early post-transplant period were adoptively transferred rather than stem-cell derived.([Figure1B](#F1){ref-type="fig"})

Early Lymphocyte Function and T-cell receptor (TCR) repertoire {#S18}
--------------------------------------------------------------

The proliferative response to PHA, tetanus toxoid, CMV, and HSV lysates was robust as early as Day +30.([Figure 4A](#F4){ref-type="fig"}) TREC and V~β~ spectratyping were available in all 100-day survivors.([Figure 4B](#F4){ref-type="fig"}) All demonstrated low TREC copy numbers, whereas the patients consistently demonstrated a good V~β~ spectratyping complexity score at the same time point. These data indicate that broad TCR repertoire could be achieved with adoptively transferred memory cells before naïve thymic output. [Figure 4C](#F4){ref-type="fig"} shows the V~β~ spectratyping from the patient with the median V~β~ spectratyping complexity score (106) at day +100.

Discussion {#S19}
==========

Adoptive transfer of CD45RA-depleted T cells and enriched NK cells in conjunction with CD34+ selected haploidentical HPCs, infused after a novel reduced intensity conditioning regimen without antibody or total body irradiation (TBI), is feasible and well tolerated in our patients with very high-risk leukemia. The first 17 consecutive patients on this study represent a very poor prognosis population of heavily pre-treated patients. All patients achieved rapid donor neutrophil engraftment, and no patient has developed acute GvHD. Tolerability is acceptable, with only two patients experiencing TRM. Importantly, no TRM was associated with infection, which is atypical in HLA-mismatched HCT. Two patients have experience relapse of their disease, and the remaining 13 patients remain alive at a median of Day +223, all in molecular remission. Continued accrual and follow-up is needed to assess long term clinical outcomes.

Profound depletion of CD45RA+ T cells was reliably obtained in all products, with a median CD3+CD45RA+ cell dose of \<10^3^/kg. Thus, despite the infusion of a median of \>100 million haploidentical T cells/kg, no patient developed acute GvHD. In addition, the majority of the pre-processing CD34+ cell population was preserved after CD45RA+ cell depletion, allowing a large progenitor cell dose to be given to all patients concurrent with the memory cell transfer. The B cell content was also substantially depleted in all grafts, abrogating the need for additional ex vivo or in vivo B cell depletion for the prevention of EBV-LPD. The processing of NK cell products was similarly successful in all cases, with minimal T and B-cell content. Collectively, infusions of the three haploidentical products were well tolerated and patients have so far experienced low rates of rejection, infection, acute GvHD, and relapse - the most common serious side effects seen early after allogeneic transplantation.

Assessment of immune reconstitution in the early post-transplant period after adoptive transfer of donor NK cells and CD45RA-depleted cells demonstrated robust reconstitution of innate and memory immunity. There is a rapid reconstitution of NK cells and CD8+ T cells to quantitatively normal values, and a substantial number of CD4+ T cells are already present by Day +30. It is clear that early post-transplant T-lymphocyte subset distribution recapitulates the CD45RA-depleted graft composition, confirming successful adoptive transfer of balanced memory T-cell populations. Both effector memory T cells and central memory T cells are present and sustainable in numbers for up to 6 months after transplantation in both the CD4+ and CD8+ T-cell populations, providing critical protection against infections before stem cell-derived thymic output. A high proportion of regulatory T cells were present early, and naïve T cells were virtually absent. This allowed successful discontinuation of GvHD prophylaxis by Day +60 without acute GvHD. Some patients have developed mild chronic GvHD, and it has predominately been responsive without the need for systemic therapy.

In addition to the rapid quantitative reconstitution of NK cells and memory T cells, early functional recovery was confirmed as well. Proliferative responses to mitogen and antigens are uniformly recovered between Day +30 and +60. There has been no development of significant CMV and EBV disease. Additionally, only one infection each from adenovirus and HSV has occurred. Although follow-up remains short, the control of HSV, CMV, EBV, and adenoviral reactivation appears much better than expected compared to our prior experience.^[@R35]^

By Day +100 after transplantation, patients uniformly demonstrated low level TREC production, but all (including those with no evidence of thymic output) demonstrated substantial V Beta spectratyping diversity. These TCR data, in combination with the predominant CD45RO+ phenotypes, support the hypothesis that the T-cell immunity in the first months after HCT was provided by successful adoptive transfer from the CD45RA-depleted grafts.

The use of HLA-mismatched donor, such as haploidentical donors, is frequently associated with an increased risk of graft failure. Some investigators use TBI to provide high level of immuno- and myeloablation.^[@R3],\ [@R10]^ However, TBI is associated with many short term and long term toxicities.^[@R36]-[@R38]^ Lymphodepleting antibodies are also often utilized to facilitate donor engraftment and reduce GvHD.^[@R18],\ [@R39]^ However, these agents have a long half-life and typically lengthen the time to donor lymphocyte reconstitution.^[@R40],\ [@R41]^ TLI has been utilized in reduced intensity regimens, and it has been associated with good engraftment, low GvHD, and low toxicity.^[@R42]-[@R44]^ In this study, the novel TLI-based reduced intensity preparative regimen has allowed patients to avoid TBI and anti-T cell antibody therapy, yet rapidly achieved neutrophil engraftment with full donor chimerism in all patients.

Although this regimen shows promise, there is substantial cost and complexity inherent in the utilization of three manipulated donor products. A cost and bed-utility analysis is underway to assess whether the short hospital stay and low cost in GvHD and infection control outweigh the cost of donor cell processing and allow more transplantations per transplant bed. If the high rate of engraftment seen to date is confirmed with additional patients, megadose of progenitor cells^[@R45]^ as utilized here, may not be required in the presence of a large memory T-cell fraction.

In conclusion, this treatment regimen demonstrated acceptable tolerability in heavily pretreated patients with poor-prognosis hematologic malignancy. CD45RA+ cell depletion and NK cell enrichment were reliable and effective procedures, providing therapeutic cell products that contain extremely low number of B and naïve T cells, but abundant memory T cells and NK cells. Complete donor engraftment was reliably achieved, with rapid normalization of neutrophil, NK cell, and CD8+ T cell counts. Early memory T-cell quantification and functional parameters are promising. There was also a low rate of acute GvHD and transplant related mortality with no infection-related deaths.
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![Flow cytometry evaluation of CD45RA-depleted product and lymphocyte reconstitution on Day 30 and Day 60\
Representative evaluation of samples from patient 6 (the patient with median tempo of immune cell reconstitution). Gates were set for CD14--, CD4+, or CD8+ cells as indicated at the top of the panels. See [supplemental figure 1](#SD1){ref-type="supplementary-material"} for post-transplant flow cytometry gating strategies from a representative umbilical cord blood recipient.](nihms-649687-f0001){#F1}

![Engraftment, immune recovery, and outcomes\
(A)Time to neutrophil engraftment (ANC \>500/μL), platelet engraftment (\>20 × 10^9^/L), and onset of acute GvHD. (B)Time to full donor chimerism, normalization of NK cell or CD8+ T cell counts. (C) Time to relapse or transplant-related mortality (TRM).](nihms-649687-f0002){#F2}

###### 

Quantitative subset analysis

Values are from all patients who were alive without relapse at each time point. Data from donors are prior to G-CSF mobilization. (A) Absolute number of T, B, and NK-lymphocytes, red line denotes median value. (B) Absolute number of CD8+CD45RA-- and CD4+CD45RA-- memory T cells, red line denotes median value. (C) Median percentage of CD25^bright^CD127^−^ regulatory T cells in the CD3+CD4+ fraction. (D-F) Average proportion of the following subsets: effector memory T cells (CD45RA^−^CD27^−^, CD45RA^−^ CCR7^−^, or CD45RA^−^CD62L^−^); central memory T cells (CD45RA^−^CD27^+^, CD45RA^−^CCR7^+^, or CD45RA^−^CD62L^+^); terminal effector memory RA+ cells (CD45RA^+^CD27^−^, CD45RA^+^CCR7^−^, or CD45RA^+^CD62L^−^); and naïve T cells (CD45RA^+^CD27^+^, CD45RA^+^CCR7^+^, or CD45RA^+^CD62L^+^)

![](nihms-649687-f0003)

![](nihms-649687-f0004)

![Functional and TCR studies\
(A)Median lymphocyte proliferation as measured by Brdu incorporation at day +30 and +60 post-transplant. Patients with CMV seropositive and seronegative donors are presented separately. (B)TCR V~β~ spectratyping score and TREC per mL of blood (log-scale) from all donors and patients who were alive without relapse at each time point, red line denotes median value. (C) Representative V~β~ spectratyping from the patient with a median V~β~ spectratyping score](nihms-649687-f0005){#F4}

###### 

Patient Summary (n=17)

  **Age**                                      
  ------------------------------------- ------ ------------
    Median (range); years               7.7    (0.6-20.3)
  **Weight**                                   
    Median (range); kg                  24.5   (6.4-158)
  **Sex**                                      
    Male                                11     (65%)
    Female                              6      (35%)
  **Race**                                     
    Caucasian                           7      (41%)
    Non-Caucasian                       10     (59%)
      Hispanic                          6      
      African American                  3      
      Mix (Asian/Hispanic)              1      
  **Disease**                                  
    Acute Lymphoblastic Leukemia        6      (35%)
      B cell                            4      
      T cell (early T-cell precursor)   2      
    Acute Myeloid Leukemia              9      (53%)
      de novo                           7      
      Therapy-related                   1      
      Myeloid sarcoma                   1      
    Mixed Lineage Leukemia              1      (6%)
    Myelodysplastic Syndrome            1      (6%)
      Therapy-related                   1      
  **Disease Stage**                            
    CR1                                 5      (29%)
      Detectable disease                1      
    Subsequent CR                       3      (18%)
      Detectable disease                1      
    Active Relapse                      3      (18%)
    Induction Failure                   4      (24%)
    Refractory Anemia                   1      (6%)
    Untreated                           1      (6%)
  **HLA match status**                         
    4 of 8                              13     (76%)
    5 of 8                              3      (18%)
    6 of 8                              1      (6%)
  **CMV status (Donor/Patient)**               
    Negative/Negative                   1      (6%)
    Positive/Positive                   8      (47%)
    Positive/Negative                   4      (24%)
    Negative/Positive                   4      (24%)

###### 

Cell counts before and after CD45RA+ cell depletion and NK-cell enrichment respectively. (n=17) (Median Values)

                                 Pre-Processing   Post-Processing   Recovery   Log Depletion
  ------------------------------ ---------------- ----------------- ---------- ---------------
  CD45RA-Depleted Product                                                      
  **TNC (×10^8^/kg)**            19.43            5.42                         
  **CD34+ (×10^6^/kg)**          11.72            6.38              59.6%      
  **CD3+ (×10^6^/kg)**           468.85           121.78                       0.58
  **CD45RA+ (×10^6^/kg)**        626.04           0.26                         3.57
  **CD3+ CD45RA+ (×10^6^/kg)**   205.57           \<0.001                      \>5.23
  **CD19+ (×10^6^/kg)**          101.60           0.15                         2.63
  **CD3−CD56+ (×10^6^/kg)**      69.05            3.53              6.31%      
  NK-cell Enriched Product                                                     
  **TNC (×10^8^/kg)**            3.72             0.14                         
  **CD3−CD56+ (×10^6^/kg)**      32.27            13.11             40.6%      
  **CD3+ (×10^6^/kg)**           235.74           0.01                         4.10
  **CD3+CD56−(×10^6^/kg)**       202.03           \<0.01                       \>4.16
  **CD19+ (×10^6^/kg)**          49.04            0.04                         3.09

###### 

Detailed Patient Summary

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  UPN   Disease       Stage       Pre-HCT\                                Combined cell\                                    Day to\   Day\      PB Chimerism\   Lymphocytes (d+30)[‡](#TFN3){ref-type="table-fn"}   Outcome   (day)                                
                                  disease\                                dose(×10^6^/kg)[\*](#TFN2){ref-type="table-fn"}   ANC\      to plt\   %donor d+30                                                                                                        
                                  burden[¥](#TFN1){ref-type="table-fn"}                                                     \>500     \>20k                                                                                                                        
  ----- ------------- ----------- --------------------------------------- ------------------------------------------------- --------- --------- --------------- --------------------------------------------------- --------- ------- ----- ----- ----- ---------- -----
  1     AML           PIF         3% (a)                                  7.62                                              45.9      0.07      13              NA                                                  100       \<10    60    300   150   Relapse    95

  2     B ALL         Relapse 1   73%                                     17.11                                             215.5     0.48      12              NE                                                  NE        NE      NE    NE    NE    TRM        13

  3     t-AML         CR1         0.01%                                   6.66                                              55.9      0.24      11              16                                                  100       \<10    100   310   90    Alive CR   469

  4     B ALL         CR2         \<0.01%                                 10.56                                             26.6      0.69      10              17                                                  99-100    \<10    190   590   130   Alive CR   442

  5     AML, M7       PIF         2.3% (c)                                28.97                                             121.8     0.09      10              17                                                  100       \<10    80    200   120   Relapse    85

  6     ETP ALL       CR1         \<0.01%                                 14.17                                             99.2      0.33      11              14                                                  100       \<10    190   280   350   Alive CR   433

  7     Infant ALL    PIF         0.04% (a)                               51.64                                             528.5     3.15      9               102                                                 100       \<10    100   300   190   Alive CR   419

  8     AML, M5       Relapse 1   3.9% (a)                                10.86                                             57.1      0.13      10              18                                                  100       \<10    320   320   260   Alive CR   363

  9     AML, M0       PIF         71%                                     18.77                                             133.6     0.63      11              15                                                  100       \<10    180   790   120   TRM        74

  10    t-MDS         RA          2%                                      35.10                                             99.21     0.82      10              15                                                  100       \<10    130   140   230   Alive CR   272

  11    AML, MLL+     CR1         \<10^−4^ (p)                            23.81                                             269.21    0.81      9               17                                                  100       \<10    140   800   110   Alive CR   223

  12    ETP ALL       CR1         \<0.01%                                 13.82                                             31.52     0.34      10              19                                                  100       \<10    310   30    160   Alive CR   216

  13    AML, FLT3+    Relapse 2   34%                                     17.8                                              200.44    0.54      12              25                                                  100       \<10    180   420   190   Alive CR   209

  14    MS, 7−        untreated   75% (f)                                 67.55                                             199.48    1.82      11              10                                                  56        10      10    80    0     Alive CR   204

  15    AML           CR2         unavailable                             25.96                                             122.08    0.87      10              17                                                  100       \<10    590   130   180   Alive CR   188

  16    Mix lineage   CR1         \<10^−4^ (p)                            23.43                                             234.05    0.60      9               11                                                  100       \<10    490   800   110   Alive CR   181

  17    B ALL         CR3         0.06%                                   3.63                                              23.58     0.10      11              35                                                  100       \<10    90    100   310   Alive CR   174
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values per flow cytometry minimal residual disease (MRD) testing unless otherwise noted: (p)=quantitative PCR, (f)=FISH, (a)=aplastic marrow, (c)=clusters of disease apparent

Total cell dose for progenitor cell grafts (CD34+ selected and CD45RA-depleted), NK infusion not included

Values listed are cells/μL; normal values based on 57 healthy children 1 − 18y: B(Bcells)=100-1620, T4(CD4+Tcells)=550-2150, T8(CD8+Tcells)=200-1400, NK(NK cells)=100-750; or based on 38 healthy adults 18 − 58y: B(Bcells)=100-770, T4(CD4+Tcells)=450-2500, T8(CD8+Tcells)=210-1300, NK(NK cells)=50-450

UPN=unique patient number, AML=acute myeloid leukemia, ALL=acute lymphoblastic leukemia, t-AML=therapy-related AML, ETP=early T-cell precursor, MS=myeloid sarcoma, PIF=primary induction failure, CR=complete remission, kg=kilogram, ANC=absolute neutrophil count, NA=not achieved, NE=not evaluable because patient expired day +13
